HEK293 human embryonic kidney cell line transfected with either (A) human IL-17 RE or (B) human IL-17 RA and eGFP was stained with Mouse Anti-Human IL-17 RE Monoclonal Antibody (Catalog # MAB8358) followed by Allophycocyanin-conjugated Anti-Mouse IgG Secondary Antibody (Catalog # F0101B). Quadrant markers were set based on control antibody staining (Catalog # MAB002). View our protocol for Staining Membrane-associated Proteins.

Applications for Human IL-17RE Antibody

Application

Recommended Usage

Blockade of Receptor-ligand Interaction

In a functional ELISA, 0.05-0.25 μg/mL of this antibody will block 50% of the binding of 10 ng/mL of Recombinant Human IL-17C (Catalog # 1234-IL) to immobilized Recombinant Human IL-17 RE Fc Chimera (Catalog # 8358-MR) coated at 0.25 μg/mL (100 μL/well). At 2.5 μg/mL, this antibody will block >80% of the binding.

CyTOF-ready

Ready to be labeled using established conjugation methods. No BSA or other carrier proteins that could interfere with conjugation.

Flow Cytometry

0.25 µg/10⁶ cells
Sample: HEK293 human embryonic kidney cell line transfected with human IL-17 RE

Please Note: Optimal dilutions of this antibody should be experimentally determined.

Formulation, Preparation, and Storage

Purification

Protein A or G purified from hybridoma culture supernatant

Endotoxin Level

<0.10 EU per 1 μg of the antibody by the LAL method.

Reconstitution

Reconstitute at 0.5 mg/mL in sterile PBS. For liquid material, refer to CoA for concentration.

Formulation

Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.

Shipping

Lyophilized product is shipped at ambient temperature. Liquid small pack size (-SP) is shipped with polar packs. Upon receipt, store immediately at the temperature recommended below.

Stability & Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.

12 months from date of receipt, -20 to -70 °C as supplied.
1 month, 2 to 8 °C under sterile conditions after reconstitution.
6 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: IL-17RE

Interleukin-17 Receptor E (IL-17 RE) is an approximately 70 kDa (predicted) transmembrane protein in the family of IL-17 receptors. IL-17 RE is required for mediating the pro-inflammatory and homeostatic actions of IL-17C in the skin and mucosa (1, 2). Mature human IL-17 RE consists of a 431 amino acid (aa) extracellular domain, a 21 aa transmembrane segment, and a 192 aa cytoplasmic domain with one SEFIR/TIR domain (3). Within aa 115-454, human IL-17 RE shares 79% aa sequence identity with mouse and rat IL-17 RE. Alternative splicing of human IL-17 RE generates additional isoforms with a 116 aa N-terminal deletion and/or substitution and truncation in the ECD following aa 268 or aa 433. IL-17 RE is expressed on keratinocytes, mucosal epithelial cells, Th17 cells, and gamma/ delta T cells (4, 5). It associates with the widely expressed IL-17 RA to form a heterodimeric receptor for IL-17C (4-6). IL-17C binds to IL-17 RE with high affinity and to IL-17 RA with low affinity (4, 5). IL-17C expression is induced by inflammatory stimulation in colon and airway epithelial cells, keratinocytes, CD4⁺ T cells, macrophages, and dendritic cells (4, 6, 7-9). It is up-regulated in various chronic inflammatory diseases including psoriasis, cystic fibrosis, and chronic obstructive pulmonary disease (COPD) (7, 8, 10). IL-17 RE is reciprocally down-regulated in psoriatic lesions (10). The interaction of IL-17C with IL-17 RE promotes mucosal immunity through the induction of anti-bacterial peptides and pro-inflammatory cytokines and chemokines (4, 6, 8, 9). IL-17C action supports the integrity of the colon epithelium following infection induced damage (4, 6, 11) but also contributes to psoriatic skin thickening and the progression of arthritis (4, 8, 9). IL-17C is additionally up-regulated in Th17 cell dependent autoimmunity (5). In this setting, it exacerbates disease severity by inducing Th17 cell production of IL-17A, IL-17F, IL-22, CCR6, and CCL20 (5). The up-regulation of IL-17 RE in hepatocellular carcinoma is associated with poor prognosis (12).

References

Pappu, R. et al. (2012) Trends Immunol. 33:343.
Rubino, S.J. et al. (2012) Trends Immunol. 33:112.
Li, T.S. et al. (2006) Cell. Signal. 18:1287.
Ramirez-Carrozzi, V. et al. (2011) Nat. Immunol. 12:1159.
Chang, S.H. et al. (2011) Immunity 35:611.
Song, X. et al. (2011) Nat. Immunol. 12:1151.
Pfeifer, P. et al. (2013) Am. J. Respir. Cell Mol. Biol. 48:415.
Johnston, A. et al. (2013) J. Immunol. 190:2252.
Yamaguchi, Y. et al. (2007) J. Immunol. 179:7128.
Johansen, C. et al. (2009) Br. J. Dermatol. 160:319.
Reynolds, J.M. et al. (2012) J. Immunol. 189:4226.
Liao, R. et al. (2013) J. Exp. Clin. Cancer Res. 32:3.

Long Name

Interleukin 17 Receptor E

Alternate Names

IL-17 RE, IL17RE, Il25r

Entrez Gene IDs

132014 (Human); 57890 (Mouse); 362417 (Rat)

Gene Symbol

IL17RE

UniProt

Q8NFR9

Additional IL-17RE Products

Product Documents for Human IL-17RE Antibody

Product Datasheets

Download Product Datasheets

COA

SDS

Download SDS

Product Specific Notices for Human IL-17RE Antibody

For research use only

Citations
Reviews

Calculators
Flow Cytometry

Human IL-17RE Antibody

R&D Systems, part of Bio-Techne | Catalog # MAB8358

Key Product Details

Species Reactivity

Validated:

Applications

Label

Antibody Source

View all IL-17RE Antibodies »

Product Summary for Human IL-17RE Antibody

Immunogen

Specificity

Clonality

Host

Isotype

Scientific Data Images for Human IL-17RE Antibody

Detection of IL-17 RE in HEK293 Human Cell Line Transfected with Human IL-17 RE and eGFP by Flow Cytometry.